Beta Radiation for MIGS Bleb Scar Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Minimally Invasive Glaucoma Surgery (MIGS) implants face complications due to scar formation and wound reversion, leading to poor drainage and reduced therapeutic effect, with existing antimetabolites like mitomycin C and 5-fluorouracil showing high failure rates and adverse effects.
Innovation Solution
The use of beta radiation in combination with MIGS implants to inhibit scar formation and fibrogenesis, applying beta radiation from isotopes such as Strontium-90, Phosphorus-32, or Yttrium-90 to maintain functioning drainage blebs and prevent bleb failure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-generated harmful factors
If antimetabolites like mitomycin C and 5-fluorouracil are used to prevent scar formation, then scar formation is reduced, but bleb failure rate increases and adverse effects occur
Solution Approach 1:
The patent changes the fundamental parameter of anti-scarring treatment from chemical antimetabolites to physical beta radiation. This parameter change allows for precise control of radiation dose and duration, achieving scar prevention without the high failure rates and adverse effects associated with chemical agents. The beta radiation source is positioned in direct contact with the bleb, delivering localized treatment that spares surrounding tissues.
Solution Approach 2:
The patent replaces the chemical mechanism of antimetabolites with a physical radiation mechanism. Beta radiation directly damages fibroblast DNA and inhibits collagen synthesis through ionizing effects, rather than requiring metabolic interference. This substitution eliminates the need for systemic absorption and metabolic activation, reducing adverse effects while maintaining local efficacy.
2Reliability
If beta radiation is applied to reduce scar formation, then bleb function is maintained, but cataract formation risk must be managed
Solution Approach 1:
The patent applies beta radiation in a highly localized manner by placing the radiation source in direct contact with the bleb tissue only. The short range of beta particles (a few millimeters in tissue) ensures that radiation is confined to the immediate treatment area, sparing the lens and other sensitive ocular structures from significant exposure. This local quality approach maintains therapeutic efficacy while minimizing systemic and distant side effects.
Solution Approach 2:
The patent uses controlled, partial exposure to beta radiation focused specifically on the bleb tissue. By limiting the radiation dose to the minimum necessary for scar prevention and using short-duration applications, the treatment achieves therapeutic effect while keeping cumulative lens exposure below cataractogenic thresholds. The radiation is applied only when and where needed, rather than continuous or excessive exposure.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Beta radiation effectively reduces scar formation and inflammation, maintaining bleb function and reducing intraocular pressure, offering a superior alternative to traditional antimetabolites with lower risk of adverse effects like cataract formation.
Implementation Method 1
The use of beta radiation in combination with MIGS implants to inhibit scar formation and fibrogenesis, applying beta radiation from isotopes such as Strontium-90, Phosphorus-32, or Yttrium-90 to maintain functioning drainage blebs
Implementation Method 2
Beta radiation effectively reduces scar formation and inflammation, maintaining bleb function
Data Source
AI summary
Methods, systems, and compositions for maintaining functioning drainage blebs to reduce intraocular pressure (IOP) of an eye being treated for glaucoma. The methods, systems, and compositions feature the combination of a minimally invasive glaucoma surgery (MIGS) implant or procedure and the application of beta radiation to the bleb. The beta radiation can function to inhibit or reduce the inflammation and/or fibrogenesis that typically occurs after insertion of a MIGS implant and leads to bleb failure. By reducing inflammation and/or fibrogenesis, the MIGS implant and the blebs can remain functioning appropriately.